Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat

BMC Pulmonary Medicine

Case Report

David S. Poch¹ 

[1]Division of Pulmonary, Critical Care, & Sleep Medicine, University of California, San Diego, CA, USA

关键词: Pulmonary arterial hypertension;    sGC stimulators;    Cyclic guanosine monophosphate;    Chronic thromboembolic pulmonary hypertension;   

DOI  :  10.1186/s12890-016-0229-x

 received in 2015-11-11, accepted in 2016-04-15,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundWe present here the case of a patient with pulmonary arterial hypertension and NYHA Class II symptoms who transitioned from PDE-5i therapy to riociguat. No protocol currently exists for transitioning between these PAH medications.Case presentationA 59-year old male with a history of anorexigen use initially presented in 2008 and was felt to have non-operable small vessel disease. His care was transitioned to our center after insurance would not cover high-dose sildenafil in addition to ERA therapy.ConclusionThis case demonstrates a safe and successful transition from higher dose PDE-5is to riociguat with no interruption in therapy.

【 授权许可】

CC BY   
© Poch. 2016